SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools (LAB) announced a transformative merger with private…

STANDARD BIOTOOLS INC. · 8-K filed Jun 8, 2026 at 08:31 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 8, 2026 at 08:31 ET

Standard BioTools (LAB) announced a transformative merger with private biotech Treeline Biosciences in an all-stock reverse-merger transaction. Treeline is valued at $2.5 billion, while LAB is valued at ~$460M based on net cash at closing. Former Treeline stockholders will own ~84% of the combined company on a fully diluted basis, with LAB holders retaining ~16%. LAB also expects to issue contingent value rights (CVRs) to its stockholders tied to proceeds from Legacy Business monetization and other sources, capped at 76 million shares. The deal requires LAB shareholder approval and is expected to close in H2 2026.

  • Reverse merger: Treeline valued at $2.5B; LAB valued at ~$460M (implied by net cash floor of $449M).
  • LAB shareholders will hold ~16% of the combined company; Treeline stockholders ~84%.
  • Exchange ratio based on relative equity values: $2.5B for Treeline, $460M for LAB with net cash adjustment bands ($449M floor, $451M ceiling).
  • Combined company to be named Treeline Biosciences Holdings, Inc.; LAB will effect a reverse stock split.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access